However, clinical trials conducted using the vorinostat/erlotinib or entinostat/erlotinib combination with NSCLC patients having EGFR activating mutations and who had already received erlotinib have shown no additive efficacy (NCT00503971) (30). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.